Vibe GrowthFRA:3ST0 +0.43%29 Net Margin % is -12.58% as of Mar. 2026. GuruFocus rates FRA:3ST0 with a GF Score™ of 29/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, Vibe Growth ranks worse than 79.08% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Vibe Growth's Net Income for the
three
months ended in Mar. 2026 was €-0.49 Mil. Vibe Growth's Revenue for the
three
months ended in Mar. 2026 was €3.89 Mil. Therefore, Vibe Growth's net margin for the quarter that ended in Mar. 2026 was -12.58%.
The historical rank and industry rank for Vibe Growth's Net Margin % or its related term are showing as below:
FRA:3ST0'
s Net Margin % Range Over the Past 10 Years
Min: -78.68 Med: -45.64 Max: 3.01
Current: -15.14
FRA:3ST0's Net Margin % is ranked worse than 79.08% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs FRA:3ST0: -15.14
Vibe Growth (FRA:3ST0) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Vibe Growth Net Margin % Related Terms
Vibe Growth Net Margin % Historical Data
* Premium members only.
The historical data trend for Vibe Growth's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vibe Growth's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vibe Growth Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vibe Growth's Net Margin % distribution charts can be found below:
* The bar in red indicates where Vibe Growth's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vibe Growth (FRA:3ST0) has a Net Margin % of -12.58% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Vibe Growth and its competitors. According to the industry distribution chart, Vibe Growth ranks #756 out of 956 companies in the Drug Manufacturers industry, placing it in the top 79.1%.
Is Vibe Growth's Net Margin % too high?
Vibe Growth's current Net Margin % is -12.58%. Based on the distribution chart, Vibe Growth ranks #756 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vibe Growth has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vibe Growth's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vibe Growth ranks #756 out of 956 companies for Net Margin %. This places Vibe Growth in the lower half of its industry. The industry median Net Margin % is 5.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Vibe Growth and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vibe Growth's current Net Margin % is -12.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vibe Growth stock overvalued right now?
Based on GuruFocus' analysis, Vibe Growth (FRA:3ST0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.23 — trading 191.3% above its estimated fair value. The current Net Margin % is -12.58%. Vibe Growth's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Vibe Growth (FRA:3ST0), the current Net Margin % is -12.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vibe Growth (FRA:3ST0) Overvalued in 2026?
Based on GuruFocus' analysis, Vibe Growth stock appears to be overvalued.
The current stock price of €0.23 is trading 191.3% above its estimated GF Value™ of €0.08.
GuruFocus considers Vibe Growth to be Significantly Overvalued.
Key valuation signals for FRA:3ST0:
Net Margin %: -12.58%
GF Value™: €0.08 vs. price of €0.23 (191.3% above fair value)
No single metric tells the full story. See the FRA:3ST0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vibe Growth Corp is engaged in the evaluation, acquisition, and development of cannabis cultivation, distribution, and manufacturing assets and retail cannabis dispensaries, predominantly in the U.S., to become a vertically integrated cannabis operator. The company currently operates four dispensaries, one distribution, and one cultivation operation in the State of California, plus one dispensary in Portland, Oregon. It offers cannabis infused products across various categories such as vaporizers, concentrates, edibles, topicals, pre-rolls, etc., and through different brands including Alien Labs, Almora Farm, Buddies, Chill Bud, Highatus, and Others.
29GF Score
Get the complete analysis for FRA:3ST0
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3ST0 has been successfully added to your 
